- Home
- CENX vs NVCR Comparison
CENX vs NVCR Comparison
Compare CENX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENX
- NVCR
- Stock Information
- Founded
- CENX 1995
- NVCR 2000
- Country
- CENX United States
- NVCR Switzerland
- Employees
- CENX N/A
- NVCR N/A
- Industry
- CENX Aluminum
- NVCR Medical/Dental Instruments
- Sector
- CENX Industrials
- NVCR Health Care
- Exchange
- CENX Nasdaq
- NVCR Nasdaq
- Market Cap
- CENX 1.7B
- NVCR 1.4B
- IPO Year
- CENX 1996
- NVCR 2015
- Fundamental
- Price
- CENX $21.70
- NVCR $11.26
- Analyst Decision
- CENX Strong Buy
- NVCR Buy
- Analyst Count
- CENX 3
- NVCR 7
- Target Price
- CENX $23.00
- NVCR $28.79
- AVG Volume (30 Days)
- CENX 1.7M
- NVCR 2.0M
- Earning Date
- CENX 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- CENX N/A
- NVCR N/A
- EPS Growth
- CENX N/A
- NVCR N/A
- EPS
- CENX 1.22
- NVCR N/A
- Revenue
- CENX $2,364,700,000.00
- NVCR $630,160,000.00
- Revenue This Year
- CENX $11.02
- NVCR $6.15
- Revenue Next Year
- CENX $1.74
- NVCR $7.35
- P/E Ratio
- CENX $17.61
- NVCR N/A
- Revenue Growth
- CENX 11.41
- NVCR 14.58
- 52 Week Low
- CENX $11.63
- NVCR $10.91
- 52 Week High
- CENX $25.39
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CENX 59.27
- NVCR 27.37
- Support Level
- CENX $22.05
- NVCR $11.07
- Resistance Level
- CENX $23.10
- NVCR $11.94
- Average True Range (ATR)
- CENX 0.88
- NVCR 0.85
- MACD
- CENX -0.17
- NVCR -0.17
- Stochastic Oscillator
- CENX 50.67
- NVCR 6.04
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.